Supplementary Figures 1 - 3, Tables 1 - 3 from Molecular Epidemiology of <i>EGFR</i> and <i>KRAS</i> Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related <i>KRAS</i>-Mutant Cancers

<p>PDF file - 225K, Supplementary Figure 1. (A) Gender differences in frequency of EGFR mutations by stage. Men with EGFR mutations presented at the late stage more often than women (118/170, 69% vs. 235/423, 56%; p=0.002); women predominated at stage I (31% vs. 19%, p=0.004). (B) Stage distribution of EGFR exon 19 del and EGFR L858R. EGFR L858R were significantly more frequent at stage I than exon 19 del (83/246, 34% vs. 82/347, 24%; p=0.009); Fisher exact test, P value <0.01 is considered significant. Supplementary Figure 2: (A) Age and (B) stage distribution of KRAS mutations (4 major subtypes) Supplementary Figure 3: EGFR mutation nomogram ROC curve in the validation cohort. Supplementary Table 1. (A) The association of the smoking-free years and pack-years of smoking with EGFR mutational status. Smoking-free years impact on likelihood of EGFR mutation. (Multivariate logistic regression analysis). (B) The association of the smoking-free years and pack-years of smoking with KRAS mutational status. Smoking-free years do not impact on likelihood of KRAS mutation. (Multivariate logistic regression analysis). Supplementary Table 2. Age and gender differences in pack-years of smoking in relation to KRAS mutation nucleotide change. Women with G>T transversions had smoked less (average 34 pack-years vs. 40 pack-years, p=0.001) and were younger than men with the same nucleotide change (median age 64 vs. 67, p=0.006). Fisher exact test, P value <0.01 is considered significant.</p>